摘要
目的该文就肺栓塞呼吸内科疾病的不同治疗方法进行探讨,并对比其临床疗效。方法整群选择2014年9月—2015年8月期间在该院接受治疗的92例患者,按照随机数字表法分成实验组(n=46)与参照组(n=46),实验组患者入院后予以瑞替普酶溶栓治疗,参照组患者入院后予以尿激酶溶栓治疗,对比两组患者的治疗总有效率、相关指标的改善程度以及不良反应。结果实验组患者的治疗总有效率为95.65%,明显高于参照组的76.09(P<0.05);实验组患者的RF、HR、Pa O_2、Pa CO_2、Sa O_2的改善程度优于参照组(P<0.05);实验组不良反应的发生率为10.87%,低于参照组的28.26%(P<0.05)。结论在肺栓塞呼吸内科疾病的临床治疗中,应用瑞替普酶溶栓治疗具有显著效果,且安全性高,值得在临床中广泛推广并应用。
Objective In this paper, the different treatment of pulmonary embolism respiratory medicine disease were discussed, and compared the clinical curative effect. Methods Group selection from in September 2014- August 2015 treated in our hospital during the period of 92 patients, according to random number table method were divided into experimental group（n = 46） and control group（n = 46）.Experimental group patients after admission to Switzerland for thrombolysis enzyme treatment, Control group patients after admission to urokinase thrombolysis treatment,compared two groups of the treatment of patients with total effective rate, improvement of related standards and adverse reactions. Results Experimental group in the treatment of patients with the total effective rate was 95.65%, significantly higher than that of control group76.09（P〈0.05）; Experimental group patients of RF, HR, PaO2, PaCO2, SaO2 improvement degree is better than that of control group（P〈0.05）; The experimental group the incidence of adverse reactions was 10.87%, less than 28.26% of the control group（P〈0.05）. Conclusion In respiratory medicine disease in the clinical treatment of pulmonary embolism, rui at enzyme thrombolysis treatment has significant effect, and high safety, is worth in the clinical application and spread.
出处
《中外医疗》
2016年第22期99-101,104,共4页
China & Foreign Medical Treatment
关键词
肺栓塞
呼吸内科
溶栓
瑞替普酶
尿激酶
Pulmonary embolism
Respiratory medicine
Thrombolysis
At the enzyme.urokinase
